Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Today, a promising treatment strategy is focused on the enhancement of antitumor immune responses by immune checkpoint modification. However, as only 20% of patients with HCC are responders, identification...

Descripción completa

Detalles Bibliográficos
Autores principales: Macek Jilkova, Zuzana, Aspord, Caroline, Kurma, Keerthi, Granon, Anouck, Sengel, Christian, Sturm, Nathalie, Marche, Patrice N., Decaens, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708670/
https://www.ncbi.nlm.nih.gov/pubmed/31295151
http://dx.doi.org/10.14309/ctg.0000000000000058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708670/
https://www.ncbi.nlm.nih.gov/pubmed/31295151
http://dx.doi.org/10.14309/ctg.0000000000000058

Ejemplares similares